Compare Amgen, Inc. (AMGN) vs Freeport-McMoRan Inc (FCX) Price & Performance

Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.

Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.